Combined immunotherapy showed a higher incidence of single or multiple endocrinopathies with respect to anti–PD–1 alone (27% vs. 9% and 7% vs. 0% respectively, p < 0.01) [91]. This evidence concerns the gene PDCD1 and endocrine system disorder.